Amubarvimab, previously known as BRII-196 , represents a significant advancement in biopharmaceutical development, particularly concerning its capacity to block the virus . This monoclonal molecule https://ztndz.com/story28776600/amubarvimab-a-deep-exploration-into-brii-196-s-prospects